Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1782, Issue 11, 2008, Pages 649-657

  Hong, Yi ^a   Yang, Junwu ^a   Wu, Weibing ^a   Wang, Wenzong ^a   Kong, Xiangfei ^a   Wang, Yanlin ^a   Yun, Xiaojing ^a   Zong, Hongliang ^a   wei, Yuanyan ^a   Zhang, Si ^a   Gu, Jianxing ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Catenin; Apoptosis; BCL2L12; Breast cancer; Cisplatin; MCF 7; MDA MB 231

Indexed keywords

BCL2L12 PROTEIN; BCL2L12A PROTEIN; BETA CATENIN; CISPLATIN; MEMBRANE PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; DOWN REGULATION; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUSCLE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 55049130997     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.09.008     Document Type: Article

References (47)

1. Snyder R.D. New concepts in breast cancer therapy. Intern. Med. J. 34 (2004) 266-269
2. Ahmedin Jemal, DVM, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu, Taylor Murray, and Michael J.Thun, Cancer Statistics, 2008. CA Cancer J Clin 58 (2008) 71-96.
3. Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin. Breast Cancer 2 (2001) 190-208
4. Crown J.P. The platinum agents: a role in breast cancer treatment?. Semin. Oncol. 28 (2001) 28-37
5. Hortobagyi G.N. Chemotherapy of breast cancer: a historical perspective. Semin. Oncol. 24 (1997) S17
6. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
7. Yazlovitskaya E.M., and Persons D.L. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res. 23 (2003) 2275-2279
8. Wei Q., Dong G., Yang T., Megyesi J., Price P.M., and Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am. J. Physiol. Renal Physiol. 293 (2007) F1282-F1291
9. Yoshida K., Ozaki T., Furuya K., Nakanishi M., Kikuchi H., Yamamoto H., Ono S., Koda T., Omura K., and Nakagawara A. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 27 (2008) 1183-1188
10. Bragado P., Armesilla A., Silva A., and Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 12 (2007) 1733-1742
11. Niedner H., Christen R., Lin X., Kondo A., and Howell S.B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacol. 60 (2001) 1153-1160
12. Funato T., Kozawa K., Kaku M., and Sasaki T. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. Anticancer Drugs 12 (2001) 829-834
13. Fraser M., Bai T., and Tsang B.K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer 122 (2008) 534-546
14. Niedner H., Christen R., Lin X., Kondo A., and Howell S.B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacol. 60 (2001) 1153-1160
15. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9 (2008) 47-59
16. Chipuk J.E., and Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 18 (2008) 157-164
17. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol.Immunol. 39 (2003) 615-647
18. Simstein R., Burow M., Parker A., Weldon C., and Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp. Biol. Med. (Maywood.) 228 (2003) 995-1003
19. Costantini P., Jacotot E., Decaudin D., and Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. 92 (2000) 1042-1053
20. Scorilas A., Kyriakopoulou L., Yousef G.M., Ashworth L.K., Kwamie A., and Diamandis E.P. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics 72 (2001) 217-221
21. Toumelin G.L., Mazars A., Licznar A., Guasconi G., Rain J.C., Cauquil N., Hickman J., and Geneste O. Bcl2L12, a new BH2 BH3 containing protein, substrate for GSK3beta, mediates UV induced apoptosis. Proc. Amer. Assoc. Cancer Res 47 (2006)
22. Talieri M., Diamandis E.P., Katsaros N., Gourgiotis D., and Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb. Haemost. 89 (2003) 1081-1088
23. Sun M., Wei Y., Yao L., Xie J., Chen X., Wang H., Jiang J., and Gu J. Identification of extracellular signal-regulated kinase 3 as a new interaction partner of cyclin D3. Biochem. Biophys. Res. Commun. 340 (2006) 209-214
24. Wang H., Shen H., Wang Y., Li Z., Yin H., Zong H., Jiang J., and Gu J. Overexpression of small glutamine-rich TPR-containing protein promotes apoptosis in 7721 cells. FEBS Lett. 579 (2005) 1279-1284
25. Herceg Z., and Wang Z.Q. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol. Cell Biol. 19 (1999) 5124-5133
26. Thomadaki H., Talieri M., and Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett. 247 (2007) 48-55
27. Reed J.C. Bcl-2 family proteins. Oncogene 17 (1998) 3225-3236
28. Reed J.C., Doctor K.S., and Godzik A. The domains of apoptosis: a genomics perspective. Sci.STKE. 2004 (2004) re9
29. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111 (2008) 3322-3330
30. Willis S., Day C.L., Hinds M.G., and Huang D.C. The Bcl-2-regulated apoptotic pathway. J. Cell Sci. 116 (2003) 4053-4056
31. Stegh A.H., Kim H., Bachoo R.M., Forloney K.L., Zhang J., Schulze H., Park K., Hannon G.J., Yuan J., Louis D.N., DePinho R.A., and Chin L. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 21 (2007) 98-111
32. Stankiewicz A.R., Lachapelle G., Foo C.P., Radicioni S.M., and Mosser D.D. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J. Biol. Chem. 280 (2005) 38729-38739
33. Gotoh T., Terada K., Oyadomari S., and Mori M. hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ. 11 (2004) 390-402
34. Ran R., Lu A., Zhang L., Tang Y., Zhu H., Xu H., Feng Y., Han C., Zhou G., Rigby A.C., and Sharp F.R. Hsp70 promotes TNF-mediated apoptosis by binding IKK gamma and impairing NF-kappa B survival signaling. Genes Dev. 18 (2004) 1466-1481
35. Wang N.S., Unkila M.T., Reineks E.Z., and Distelhorst C.W. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J. Biol. Chem. 276 (2001) 44117-44128
36. Uhlmann E.J., Subramanian T., Vater C.A., Lutz R., and Chinnadurai G. A potent cell death activity associated with transient high level expression of BCL-2. J. Biol. Chem. 273 (1998) 17926-17932
37. Mathioudaki K., Scorilas A., Papadokostopoulou A., Xynopoulos D., Arnogianaki N., Agnanti N., and Talieri M. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol. Chem. 385 (2004) 779-783
38. Thomadaki H., and Scorilas A. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann. N.Y. Acad. Sci. 1095 (2007) 35-44
39. Floros K.V., Thomadaki H., Florou D., Talieri M., and Scorilas A. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann. N.Y. Acad. Sci. 1090 (2006) 89-97
40. Floros K.V., Talieri M., and Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol. Chem. 387 (2006) 1629-1633
41. Thomadaki H., Talieri M., and Scorilas A. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol. Chem. 387 (2006) 1081-1086
42. Floros K.V., Thomadaki H., Katsaros N., Talieri M., and Scorilas A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol. Chem. 385 (2004) 1099-1103
43. Floros K.V., Thomadaki H., Lallas G., Katsaros N., Talieri M., and Scorilas A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann. N.Y. Acad. Sci. 1010 (2003) 153-158
44. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J.Biol.Chem. 269 (1994) 787-790
45. Peifer M. -βcatenin as oncogene: the smoking gun. Science 275 (1997) 1752-1753
46. Bowerman B. Oxidative stress and cancer: β-catenin convergence. Science 308 (2005) 1119-1120
47. Chen Y.Z. APP induces neuronal apoptosis through APP-BP1-mediated downregulation of β-catenin. Apoptosis 9 (2004) 415-422